1887

Journal of General Virology header logo

Volume 88, Issue 2

Ribavirin, human convalescent plasma and anti- integrin antibody inhibit infection by in the deer mouse model Free

Abstract

The New World hantavirus (SNV) is an aetiological agent for the often-fatal hantavirus cardiopulmonary syndrome (HCPS). There is no disease model for SNV and specific treatments for HCPS do not exist. By using the deer mouse infectious model, the inhibitory potential of ribavirin, human anti-SNV immune plasma (HIP), an anti-3 antibody (ReoPro) and a polyclonal rabbit anti-recombinant nucleocapsid (N) antibody against SNV was investigated. Concurrent intraperitoneal administration of 100 mg ribavirin kg prevented seroconversion in all mice at day 15 post-inoculation (p.i.). No evidence of infection was detectable by immunohistochemical staining or by quantitative RT-PCR in two of these six mice. Lower doses of ribavirin, between 5 and 50 mg kg, were much less effective at inhibiting infection. Mice given 200 μl aliquots of dilutions as high as 1 : 20 of HIP (neutralizing-antibody titre 800) failed to seroconvert by day 15 p.i. SNV N antigen staining and viral S genome were undetectable in these mice. A subset of mice given higher dilutions of HIP became infected. Treatment with 6 mg ReoPro kg did not prevent seroconversion, but was able to reduce viral load. Mice treated with 200 μl anti-N antibody or negative human plasma seroconverted when challenged with SNV, and antigen staining and viral loads were comparable to those seen in untreated controls. These results show that ReoPro can lower viral loads and that ribavirin and HIP, but not anti-N antibody, inhibit seroconversion and reduce viral loads in a dose-dependent manner.

  • Received:
  • Accepted:
  • Published Online:
SGM
Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.82459-0
2007-02-01
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/jgv/88/2/493.html?itemId=/content/journal/jgv/10.1099/vir.0.82459-0&mimeType=html&fmt=ahah

References

  1. Bharadwaj M., Lyons C. R., Wortman I. A., Hjelle B. 1999; Intramuscular inoculation of Sin Nombre hantavirus cDNAs induces cellular and humoral immune responses in BALB/c mice. Vaccine 17:2836–2843 [CrossRef]
     [Google Scholar]
  2. Bharadwaj M., Nofchissey R., Goade D., Koster F., Hjelle B. 2000; Humoral immune responses in the hantavirus cardiopulmonary syndrome. J Infect Dis 182:43–48 [CrossRef]
     [Google Scholar]
  3. Bharadwaj M., Mirowsky K., Ye C., Botten J., Masten B., Yee J., Lyons C. R., Hjelle B. 2002; Genetic vaccines protect against Sin Nombre hantavirus challenge in the deer mouse ( Peromyscus maniculatus ). J Gen Virol 83:1745–1751
     [Google Scholar]
  4. Booth C. M., Matukas L. M., Tomlinson G. A., Rachlis A. R., Rose D. B., Dwosh H. A., Walmsley S. L., Mazzulli T., Avendano M. other authors 2003; Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 289:2801–2809 [CrossRef]
     [Google Scholar]
  5. Borio L., Inglesby T., Peters C. J., Schmaljohn A. L., Hughes J. M., Jahrling P. B., Ksiazek T., Johnson K. M., Meyerhoff A. other authors 2002; Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 287:2391–2405 [CrossRef]
     [Google Scholar]
  6. Botten J., Mirowsky K., Kusewitt D., Bharadwaj M., Yee J., Ricci R., Feddersen R. M., Hjelle B. 2000a; Experimental infection model for Sin Nombre hantavirus in the deer mouse ( Peromyscus maniculatus ). Proc Natl Acad Sci U S A 97:10578–10583 [CrossRef]
     [Google Scholar]
  7. Botten J., Nofchissey R., Kirkendoll-Ahern H., Rodriguez-Moran P., Wortman I. A., Goade D., Yates T., Hjelle B. 2000b; Outdoor facility for quarantine of wild rodents infected with hantavirus. J Mammal 81:250–259 [CrossRef]
     [Google Scholar]
  8. Botten J., Ricci R., Hjelle B. 2001; Establishment of a deer mouse ( Peromyscus maniculatus rufinus ) breeding colony from wild-caught founders: comparison of reproductive performance of wild-caught and laboratory-reared pairs. Comp Med 51:314–318
     [Google Scholar]
  9. Botten J., Mirowsky K., Kusewitt D., Ye C., Gottlieb K., Prescott J., Hjelle B. 2003; Persistent Sin Nombre virus infection in the deer mouse ( Peromyscus maniculatus ) model: sites of replication and strand-specific expression. J Virol 77:1540–1550 [CrossRef]
     [Google Scholar]
  10. Canonico P. G., Kende M., Luscri B. J., Huggins J. W. 1984; In-vivo activity of antivirals against exotic RNA viral infections. J Antimicrob Chemother 14 (Suppl. A):27–41
     [Google Scholar]
  11. Chapman L. E., Mertz G. J., Peters C. J., Jolson H. M., Khan A. S., Ksiazek T. G., Koster F. T., Baum K. F., Rollin P. E. other authors 1999; Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group. Antivir Ther 4:211–219
     [Google Scholar]
  12. Coller B. S., Anderson K., Weisman H. F. 1995; New antiplatelet agents: platelet GPIIb/IIIa antagonists. Thromb Haemost 74:302–308
     [Google Scholar]
  13. Crowley M. R., Katz R. W., Kessler R., Simpson S. Q., Levy H., Hallin G. W., Cappon J., Krahling J. B., Wernly J. 1998; Successful treatment of adults with severe Hantavirus pulmonary syndrome with extracorporeal membrane oxygenation. Crit Care Med 26:409–414 [CrossRef]
     [Google Scholar]
  14. Custer D. M., Thompson E., Schmaljohn C. S., Ksiazek T. G., Hooper J. W. 2003; Active and passive vaccination against hantavirus pulmonary syndrome with Andes virus M genome segment-based DNA vaccine. J Virol 77:9894–9905 [CrossRef]
     [Google Scholar]
  15. Enria D. A., Briggiler A. M., Fernandez N. J., Levis S. C., Maiztegui J. I. 1984; Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma. Lancet ii:255–256
     [Google Scholar]
  16. Gavrilovskaya I. N., Shepley M., Shaw R., Ginsberg M. H., Mackow E. R. 1998; β 3 Integrins mediate the cellular entry of hantaviruses that cause respiratory failure. Proc Natl Acad Sci U S A 95:7074–7079 [CrossRef]
     [Google Scholar]
  17. Gavrilovskaya I. N., Brown E. J., Ginsberg M. H., Mackow E. R. 1999; Cellular entry of hantaviruses which cause hemorrhagic fever with renal syndrome is mediated by β 3 integrins. J Virol 73:3951–3959
     [Google Scholar]
  18. Hansen R. J., Balthasar J. P. 2001; Pharmacokinetics, pharmacodynamics, and platelet binding of an anti-glycoprotein IIb/IIIa monoclonal antibody (7E3) in the rat: a quantitative rat model of immune thrombocytopenic purpura. J Pharmacol Exp Ther 298:165–171
     [Google Scholar]
  19. Hooper J. W., Larsen T., Custer D. M., Schmaljohn C. S. 2001; A lethal disease model for hantavirus pulmonary syndrome. Virology 289:6–14 [CrossRef]
     [Google Scholar]
  20. Huggins J. W., Kim G. R., Brand O. M., McKee K. T., Jr. 1986; Ribavirin therapy for Hantaan virus infection in suckling mice. J Infect Dis 153:489–497 [CrossRef]
     [Google Scholar]
  21. Huggins J. W., Hsiang C. M., Cosgriff T. M., Guang M. Y., Smith J. I., Wu Z. O., LeDuc J. W., Zheng Z. M., Meegan J. M. other authors 1991; Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis 164:1119–1127 [CrossRef]
     [Google Scholar]
  22. Jahrling P. B., Peters C. J. 1984; Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain. Infect Immun 44:528–533
     [Google Scholar]
  23. Johnson K. M. 1993; Ribavirin treatment of arenavirus, hantavirus, pneumovirus, and paramyxovirus disease. In Antiviral Chemotherapy: New Directions for Clinical Application and Research pp  229–249 Edited by Mills J., Corey L. Englewood Cliffs, NJ: Prentice Hall;
     [Google Scholar]
  24. Jonsson C. B., Schmaljohn C. S. 2001; Replication of hantaviruses. Curr Top Microbiol Immunol 256:15–32
     [Google Scholar]
  25. Kamrud K. I., Hooper J. W., Elgh F., Schmaljohn C. S. 1999; Comparison of the protective efficacy of naked DNA, DNA-based Sindbis replicon, and packaged Sindbis replicon vectors expressing Hantavirus structural genes in hamsters. Virology 263:209–219 [CrossRef]
     [Google Scholar]
  26. Kirsi J. J., North J. A., McKernan P. A., Murray B. K., Canonico P. G., Huggins J. W., Srivastava P. C., Robins R. K. 1983; Broad-spectrum antiviral activity of 2- β -d-ribofuranosylselenazole-4-carboxamide, a new antiviral agent. Antimicrob Agents Chemother 24:353–361 [CrossRef]
     [Google Scholar]
  27. Larson R. S., Brown D. C., Ye C., Hjelle B. 2005; Peptide antagonists that inhibit Sin Nombre virus and Hantaan virus entry through the β 3-integrin receptor. J Virol 79:7319–7326 [CrossRef]
     [Google Scholar]
  28. Lee J. S., Lahdevirta J., Koster F., Levy H. 1999; Clinical manifestations and treatment of HFRS and HPS. In Manual of Hemorrhagic Fever with Renal Syndrome and Hantavirus Pulmonary Syndrome . pp  17–38 Edited by Lee H. W., Calisher C., Schmaljohn C. Seoul: WHO Collaborating Center for Virus Reference and Research (Hantavirus), Asian Institute for Life Sciences;
  29. Leifer E., Gocke D. J., Bourne H. 1970; Lassa fever, a new virus disease of man from West Africa. II. Report of a laboratory-acquired infection treated with plasma from a person recently recovered from the disease. Am J Trop Med Hyg 19:677–679
     [Google Scholar]
  30. Lundkvist A., Vapalahti O., Plyusnin A., Sjolander K. B., Niklasson B., Vaheri A. 1996; Characterization of Tula virus antigenic determinants defined by monoclonal antibodies raised against baculovirus-expressed nucleocapsid protein. Virus Res 45:29–44 [CrossRef]
     [Google Scholar]
  31. Mackow E. R., Ginsberg M. H., Gavrilovskaya I. N. 1999; Beta3 integrins mediate the cellular entry of pathogenic hantaviruses. In Factors in the Emergence and Control of Rodent-Borne Viral Diseases (Hantaviral and Arenal Diseases) pp  113–223 Edited by Saluzzo J. F., Dobet B. Paris: Elsevier;
     [Google Scholar]
  32. Maiztegui J. I., Fernandez N. J., de Damilano A. J. 1979; Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet ii:1216–1217
     [Google Scholar]
  33. McKee K. T. Jr, Huggins J. W., Trahan C. J., Mahlandt B. G. 1988; Ribavirin prophylaxis and therapy for experimental Argentine hemorrhagic fever. Antimicrob Agents Chemother 32:1304–1309 [CrossRef]
     [Google Scholar]
  34. Mertz G. J., Hjelle B. L., Bryan R. T. 1997; Hantavirus infection. Adv Intern Med 42:369–421
     [Google Scholar]
  35. Mertz G. J., Miedzinski L., Goade D., Pavia A. T., Hjelle B., Hansbarger C. O., Levy H., Koster F. T., Baum K. other authors 2004; Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin Infect Dis 39:1307–1313 [CrossRef]
     [Google Scholar]
  36. Mills J. N., Yates T. L., Childs J. E., Parmenter R. R., Ksiazek T. G., Rollin P. E., Peters C. J. 1995; Guidelines for working with rodents potentially infected with hantavirus. J Mammal 76:716–722 [CrossRef]
     [Google Scholar]
  37. Nolte K. B., Feddersen R. M., Foucar K., Zaki S. R., Koster F. T., Madar D., Merlin T. L., McFeeley P. J., Umland E. T., Zumwalt R. E. 1995; Hantavirus pulmonary syndrome in the United States: a pathological description of a disease caused by a new agent. Hum Pathol 26:110–120 [CrossRef]
     [Google Scholar]
  38. Ramos M. M., Overturf G. D., Crowley M. R., Rosenberg R. B., Hjelle B. 2001; Infection with Sin Nombre hantavirus: clinical presentation and outcome in children and adolescents. Pediatrics 108:E27 [CrossRef]
     [Google Scholar]
  39. Raymond T., Gorbunova E., Gavrilovskaya I. N., Mackow E. R. 2005; Pathogenic hantaviruses bind plexin–semaphorin–integrin domains present at the apex of inactive, bent α v β 3 integrin conformers. Proc Natl Acad Sci U S A 102:1163–1168 [CrossRef]
     [Google Scholar]
  40. Sassoli P. M., Emmell E. L., Tam S. H., Trikha M., Zhou Z., Jordan R. E., Nakada M. T. 2001; 7E3 F(ab′)2, an effective antagonist of rat α IIb β 3 and α v β 3, blocks in vivo thrombus formation and in vitro angiogenesis. Thromb Haemost 85:896–902
     [Google Scholar]
  41. Schmaljohn C., Hjelle B. 1997; Hantaviruses: a global disease problem. Emerg Infect Dis 3:95–104 [CrossRef]
     [Google Scholar]
  42. Schmaljohn C. S., Chu Y. K., Schmaljohn A. L., Dalrymple J. M. 1990; Antigenic subunits of Hantaan virus expressed by baculovirus and vaccinia virus recombinants. J Virol 64:3162–3170
     [Google Scholar]
  43. Severson W. E., Schmaljohn C. S., Javadian A., Jonsson C. B. 2003; Ribavirin causes error catastrophe during Hantaan virus replication. J Virol 77:481–488 [CrossRef]
     [Google Scholar]
  44. Terajima M., Hendershot J. D. III, Kariwa H., Koster F. T., Hjelle B., Goade D., DeFronzo M. C., Ennis F. A. 1999; High levels of viremia in patients with the Hantavirus pulmonary syndrome. J Infect Dis 180:2030–2034 [CrossRef]
     [Google Scholar]
  45. Xiao R., Yang S., Koster F., Ye C., Stidley C., Hjelle B. 2006; Sin Nombre viral RNA load in patients with hantavirus cardiopulmonary syndrome. J Infect Dis 194:1403–1409 [CrossRef]
     [Google Scholar]
  46. Ye C., Prescott J., Nofchissey R., Goade D., Hjelle B. 2004; Neutralizing antibodies and Sin Nombre virus RNA after recovery from hantavirus cardiopulmonary syndrome. Emerg Infect Dis 10:478–482
     [Google Scholar]
  47. Yee J., Wortman I. A., Nofchissey R. A., Goade D., Bennett S. G., Webb J. P., Irwin W., Hjelle B. 2003; Rapid and simple method for screening wild rodents for antibodies to Sin Nombre hantavirus. J Wildl Dis 39:271–277 [CrossRef]
     [Google Scholar]
  48. Yoshimatsu K., Yoo Y. C., Yoshida R., Ishihara C., Azuma I., Arikawa J. 1993; Protective immunity of Hantaan virus nucleocapsid and envelope protein studied using baculovirus-expressed proteins. Arch Virol 130:365–376 [CrossRef]
     [Google Scholar]
  49. Zaki S. R., Greer P. W., Coffield L. M., Goldsmith C. S., Nolte K. B., Foucar K., Feddersen R. M., Zumwalt R. E., Miller G. L. other authors 1995; Hantavirus pulmonary syndrome. Pathogenesis of an emerging infectious disease. Am J Pathol 146:552–579
     [Google Scholar]
  50. Zhang X. K., Takashima I., Hashimoto N. 1989; Characteristics of passive immunity against hantavirus infection in rats. Arch Virol 105:235–246 [CrossRef]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.82459-0
Loading
Ribavirin, human convalescent plasma and anti-β3 integrin antibody inhibit infection by Sin Nombre virus in the deer mouse model
J. Gen. Virol. 88, 493 (2007); https://doi.org/10.1099/vir.0.82459-0
/content/journal/jgv/10.1099/vir.0.82459-0
/content/journal/jgv/10.1099/vir.0.82459-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error